Literature DB >> 25721320

Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Wolfgang Peter Fendler1, Harun Ilhan, Philipp M Paprottka, Tobias F Jakobs, Volker Heinemann, Peter Bartenstein, Feras Khalaf, Samer Ezziddin, Marcus Hacker, Alexander R Haug.   

Abstract

OBJECTIVES: Pre-therapeutic prediction of outcome is important for clinicians and patients in determining whether selective internal radiation therapy (SIRT) is indicated for hepatic metastases of colorectal cancer (CRC).
METHODS: Pre-therapeutic characteristics of 100 patients with colorectal liver metastases (CRLM) treated by radioembolization were analyzed to develop a nomogram for predicting survival. Prognostic factors were selected by univariate Cox regression analysis and subsequent tested by multivariate analysis for predicting patient survival. The nomogram was validated with reference to an external patient cohort (n = 25) from the Bonn University Department of Nuclear Medicine.
RESULTS: Of the 13 parameters tested, four were independently associated with reduced patient survival in multivariate analysis. These parameters included no liver surgery before SIRT (HR:1.81, p = 0.014), CEA serum level ≥ 150 ng/ml (HR:2.08, p = 0.001), transaminase toxicity level ≥2.5× upper limit of normal (HR:2.82, p = 0.001), and summed computed tomography (CT) size of the largest two liver lesions ≥10 cm (HR:2.31, p < 0.001). The area under the receiver-operating characteristic curve for our prediction model was 0.83 for the external patient cohort, indicating superior performance of our multivariate model compared to a model ignoring covariates.
CONCLUSIONS: The nomogram developed in our study entailing four pre-therapeutic parameters gives good prediction of patient survival post SIRT. KEY POINTS: • Four individual parameters predicted reduced survival following SIRT in CRC. • These parameters were combined into a nomogram of pre-therapeutic risk stratification. • The model provided good prediction of survival in two independent patient cohorts.

Entities:  

Mesh:

Year:  2015        PMID: 25721320     DOI: 10.1007/s00330-015-3658-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival.

Authors:  A Veltri; T Guarnieri; C Gazzera; M Busso; F Solitro; G Fora; P Racca
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

2.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.

Authors:  Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2006-12-06       Impact factor: 5.315

3.  Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience.

Authors:  Andrew S Kennedy; Douglas Coldwell; Charles Nutting; Ravi Murthy; Daniel E Wertman; Stephen P Loehr; Carroll Overton; Steven Meranze; Jerry Niedzwiecki; Scott Sailer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

4.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

5.  Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases.

Authors:  Ralf Konopke; Stephan Kersting; Marius Distler; Jeannine Dietrich; Jörg Gastmeier; Axel Heller; Eberhard Kulisch; Hans-Detlev Saeger
Journal:  Liver Int       Date:  2008-07-29       Impact factor: 5.828

6.  Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.

Authors:  Junichi Shindoh; Evelyne M Loyer; Scott Kopetz; Piyaporn Boonsirikamchai; Dipen M Maru; Yun Shin Chun; Giuseppe Zimmitti; Steven A Curley; Chusilp Charnsangavej; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

7.  A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection.

Authors:  Ikuo Nagashima; Tadahiro Takada; Keiji Matsuda; Miki Adachi; Hirokazu Nagawa; Tetsuichiro Muto; Kota Okinaga
Journal:  J Hepatobiliary Pancreat Surg       Date:  2004

8.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

9.  Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Authors:  Wolfgang Peter Fendler; Donfack Beauclair Philippe Tiega; Harun Ilhan; Philipp M Paprottka; Volker Heinemann; Tobias F Jakobs; Peter Bartenstein; Marcus Hacker; Alexander Robert Haug
Journal:  J Nucl Med       Date:  2013-05-31       Impact factor: 10.057

10.  Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.

Authors:  Andrew S Kennedy; Patrick McNeillie; William A Dezarn; Charles Nutting; Bruno Sangro; Dan Wertman; Michael Garafalo; David Liu; Douglas Coldwell; Michael Savin; Tobias Jakobs; Steven Rose; Richard Warner; Dennis Carter; Stephen Sapareto; Subir Nag; Seza Gulec; Allison Calkins; Vanessa L Gates; Riad Salem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-20       Impact factor: 7.038

View more
  9 in total

1.  Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.

Authors:  K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

2.  Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer.

Authors:  T F Jakobs; K J Paprottka; F Raeßler; F Strobl; S Lehner; H Ilhan; C G Trumm; W P Fendler; W Sommer; P M Paprottka
Journal:  Eur Radiol       Date:  2016-04-08       Impact factor: 5.315

Review 3.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

4.  Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases.

Authors:  Ieva Kurilova; Regina G H Beets-Tan; Jessica Flynn; Mithat Gönen; Gary Ulaner; Elena N Petre; F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Elisabeth G Klompenhouwer; Andrea Cercek; Nancy A Kemeny; Constantinos T Sofocleous
Journal:  Clin Colorectal Cancer       Date:  2018-09-13       Impact factor: 4.481

Review 5.  Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.

Authors:  Alyson L Mahar; Carolyn Compton; Susan Halabi; Kenneth R Hess; Martin R Weiser; Patti A Groome
Journal:  J Surg Oncol       Date:  2017-08-02       Impact factor: 3.454

Review 6.  Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Hyun S Kim
Journal:  Oncotarget       Date:  2017-06-06

7.  Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.

Authors:  Ellen G Engelhardt; Dóra Révész; Hans J Tamminga; Cornelis J A Punt; Miriam Koopman; Bregje D Onwuteaka-Philipsen; Ewout W Steyerberg; Henrica C W de Vet; Veerle M H Coupé
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-14       Impact factor: 2.796

8.  Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.

Authors:  Diana Cornelia Moisuc; Mihai Vasile Marinca; Bogdan Gafton; Teodora Alexa-Stratulat; Mariana Pavel-Tanasa; Petru Cianga
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

9.  INHBA is a prognostic predictor for patients with colon adenocarcinoma.

Authors:  Xueying Li; Weiming Yu; Chao Liang; Yuan Xu; Miaozun Zhang; Xiaoyun Ding; Xianlei Cai
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.